New inhaler propellant put to the test in healthy volunteers

NCT ID NCT06506266

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed phase 1 study in 24 healthy adults compared a new inhaler propellant (HFA-152a) to a standard one (HFA-134a) to see if it affects how the lungs clear mucus. Participants inhaled each propellant for several days, and lung clearance was measured using a radioactive tracer. The goal is to ensure the new propellant is safe for use in asthma inhalers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HFA-152a (a propellant used in inhalers)
What this could lead to
If HFA-152a is shown to be safe and not harm lung clearance, it could become a more environmentally friendly propellant for asthma inhalers.
What could go wrong
This is a very early, small study in healthy people, not those with asthma. It only measures lung clearance, not whether the propellant works for treating asthma. Results may not apply to patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • GSK Investigational Site

    Nottingham, NG11 6JS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.